Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：47

作者：

Ulhaq, Zulvikar Syambani ^{[1
]}

Soraya, Gita Vita ^{[2
]}

机构：

[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia

[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia

来源：

MEDICINA CLINICA | 2020年 / 155卷 / 12期

关键词：

OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;

D O I：

10.1016/j.medcli.2020.07.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：548 / 556

页数：9

共 50 条

[21] IL-6 AND IL-18 CYTOKINE TRAPS IN COVID-19
Korotaeva, A. A.
Samoilova, E., V
Chepurnova, D. A.
Pogosova, N., V
Kuchiev, D.
Paleev, F. N.
INFEKTSIYA I IMMUNITET, 2024, 14 (03): : 411 - 415
[22] Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling
Zizzo, Gaetano
Tamburello, Antonio
Castelnovo, Laura
Laria, Antonella
Mumoli, Nicola
Faggioli, Paola Maria
Stefani, Ilario
Mazzone, Antonino
FRONTIERS IN IMMUNOLOGY, 2022, 13
[23] Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6
Quartuccio, Luca
Sonaglia, Arianna
Pecori, Davide
Peghin, Maddalena
Fabris, Martina
Tascini, Carlo
De Vita, Salvatore
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (11) : 2852 - 2856
[24] Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Mazzoni, Alessio
Salvati, Lorenzo
Maggi, Laura
Capone, Manuela
Vanni, Anna
Spinicci, Michele
Mencarini, Jessica
Caporale, Roberto
Peruzzi, Benedetta
Antonelli, Alberto
Trotta, Michele
Zammarchi, Lorenzo
Ciani, Luca
Gori, Leonardo
Lazzeri, Chiara
Matucci, Andrea
Vultaggio, Alessandra
Rossi, Oliviero
Almerigogna, Fabio
Parronchi, Paola
Fontanari, Paolo
Lavorini, Federico
Peris, Adriano
Rossolini, Gian Maria
Bartoloni, Alessandro
Romagnani, Sergio
Liotta, Francesco
Annunziato, Francesco
Cosmi, Lorenzo
JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (09) : 4694 - 4703
[25] The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis
Ohsugi, Yoshiyuki
Kishimoto, Tadamitsu
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (05) : 669 - 681
[26] Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
Flisiak, Robert
Jaroszewicz, Jerzy
Rogalska, Magdalena
Lapinski, Tadeusz
Berkan-Kawinska, Aleksandra
Bolewska, Beata
Tudrujek-Zdunek, Magdalena
Kozielewicz, Dorota
Rorat, Marta
Leszczynski, Piotr
Klos, Krzysztof
Kowalska, Justyna
Pabjan, Pawel
Piekarska, Anna
Mozer-Lisewska, Iwona
Tomasiewicz, Krzysztof
Pawlowska, Malgorzata
Simon, Krzysztof
Polanska, Joanna
Zarebska-Michaluk, Dorota
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
[27] Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells
Noguchi-Sasaki, Mariko
Sasaki, Yusuke
Shimonaka, Yasushi
Mori, Kazushige
Fujimoto-Ouchi, Kaori
BMC CANCER, 2016, 16
[28] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
Araki, Manabu
Matsuoka, Takako
Miyamoto, Katsuichi
Kusunoki, Susumu
Okamoto, Tomoko
Murata, Miho
Miyake, Sachiko
Aranami, Toshimasa
Yamamura, Takashi
NEUROLOGY, 2014, 82 (15) : 1302 - 1306
[29] Increase of Hemoglobin Levels by Anti-IL-6 Receptor Antibody (Tocilizumab) in Rheumatoid Arthritis
Hashimoto, Motomu
Fujii, Takao
Hamaguchi, Masahide
Furu, Moritoshi
Ito, Hiromu
Terao, Chikashi
Yamamoto, Keiichi
Yamamoto, Wataru
Matsuo, Takashi
Mori, Masato
Ohmura, Koichiro
Kawabata, Hiroshi
Mimori, Tsuneyo
PLOS ONE, 2014, 9 (05):
[30] ANTI-IL-6 ANTIBODY TREATMENT BUT NOT IL-6 KNOCKOUT IMPROVES INTESTINAL BARRIER FUNCTION AND REDUCES INFLAMMATION AFTER BINGE ETHANOL EXPOSURE AND BURN INJURY
Zahs, Anita
Bird, Melanie D.
Ramirez, Luis
Choudhry, Mashkoor A.
Kovacs, Elizabeth J.
SHOCK, 2013, 39 (04): : 373 - 379

← 1 2 3 4 5 →